Effects of HNE-modification induced by Aβ on neprilysin expression and activity in SH-SY5Y cells

Journal of Neurochemistry

Volumn 108, Issue 4, 2009, Pages 1072-1082

  Wang, Rui ^a   Wang, Suqing ^a,c   Malter, James S ^a   Wang, Deng Shun ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Department of Pathology and Laboratory Medicine ^*  (United States)

^c WUHAN UNIVERSITY   (China)

Author keywords

amyloid; 4 hydroxy nonenal; Alzheimer's disease; Degradation; Neprilysin; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA;

ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN SECRETION;

ALDEHYDES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CELL LINE, TUMOR; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NEPRILYSIN; NEURONS; PEPTIDE FRAGMENTS; RNA, MESSENGER; UP-REGULATION;

EID: 58549086590     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05855.x     Document Type: Article

References (61)

1. Ando Y., Brannstrom T., Uchida K. et al. (1998) Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J. Neurol. Sci. 156, 172 176.
2. Apelt J., Ach K. Schliebs R. (2003) Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci. Lett. 339, 183 186.
3. Bard F., Cannon C., Barbour R. et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916 919.
4. Butterfield D. A. Lauderback C. M. (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32, 1050 1060.
5. Butterfield D. A., Drake J., Pocernich C. Castegna A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med. 7, 548 554.
6. Caccamo A., Oddo S., Sugarman M. C., Akbari Y. LaFerla F. M. (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol. Aging 26, 645 654.
7. Canevari L., Abramov A. Y. Duchen M. R. (2004) Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem. Res. 29, 637 650.
8. Carson J. A. Turner A. J. (2002) Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J. Neurochem. 81, 1 8.
9. Crouch P. J., Harding S. M., White A. R., Camakaris J., Bush A. I. Masters C. L. (2008) Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int. J. Biochem. Cell Biol. 40, 181 198.
10. David D. C., Hauptmann S., Scherping I. et al. (2005) Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 280, 23802 23814.
11. Eckman E. A. Eckman C. B. (2005) Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33, 1101 1105.
12. El-Amouri S. S., Zhu H., Yu J., Gage F. H., Verma I. M. Kindy M. S. (2007) Neprilysin protects neurons against Abeta peptide toxicity. Brain Res. 1152, 191 200.
13. Esterbauer H., Schaur R. J. Zollner H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11, 81 128.
14. Farrer M., Kachergus J., Forno L. et al. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55, 174 179.
15. Forman M. S., Trojanowski J. Q. Lee V. M. (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10, 1055 1063.
16. Frautschy S. A., Yang F., Calderon L. Cole G. M. (1996) Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Neurobiol. Aging 17, 311 321.
17. Hardy J. (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154 159.
18. Hardy J. Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353 356.
19. Harman D. (1993) Free radical involvement in aging. Pathophysiology and therapeutic implications. Drugs Aging 3, 60 80.
20. Higuchi M., Iwata N. Saido T. C. (2005) Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim. Biophys. Acta 1751, 60 67.
21. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N. P., Gerard C., Hama E., Lee H. J. Saido T. C. (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292, 1550 1552.
22. Iwata N., Takaki Y., Fukami S., Tsubuki S. Saido T. C. (2002) Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70, 493 500.
23. Iwata N., Mizukami H., Shirotani K., Takaki Y., Muramatsu S., Lu B., Gerard N. P., Gerard C., Ozawa K. Saido T. C. (2004) Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J. Neurosci. 24, 991 998.
24. Johnson G. D. Ahn K. (2000) Development of an internally quenched fluorescent substrate selective for endothelin-converting enzyme-1. Anal. Biochem. 286, 112 118.
25. Kowall N. W., McKee A. C., Yankner B. A. Beal M. F. (1992) In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. Neurobiol. Aging 13, 537 542.
26. Mark R. J., Lovell M. A., Markesbery W. R., Uchida K. Mattson M. P. (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68, 255 264.
27. Marr R. A., Guan H., Rockenstein E., Kindy M., Gage F. H., Verma I., Masliah E. Hersh L. B. (2004) Neprilysin regulates amyloid beta peptide levels. J. Mol. Neurosci. 22, 5 11.
28. Miners J. S., Verbeek M. M., Rikkert M. O., Kehoe P. G. Love S. (2008) Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J. Neurosci. Methods 167, 229 236.
29. Montine T. J., Amarnath V., Martin M. E., Strittmatter W. J. Graham D. G. (1996) E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am. J. Pathol. 148, 89 93.
30. Nunomura A., Perry G., Aliev G. et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759 767.
31. Nunomura A., Chiba S., Lippa C. F., Cras P., Kalaria R. N., Takeda A., Honda K., Smith M. A. Perry G. (2004) Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol Dis. 17, 108 113.
32. Olanow C. W. (1993) A radical hypothesis for neurodegeneration. Trends Neurosci. 16, 439 444.
33. Pike C. J., Walencewicz-Wasserman A. J., Kosmoski J., Cribbs D. H., Glabe C. G. Cotman C. W. (1995) Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64, 253 265.
34. Pratico D., MY Lee V., Trojanowski J. Q., Rokach J. Fitzgerald G. A. (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12, 1777 1783.
35. Russo R., Borghi R., Markesbery W., Tabaton M. Piccini A. (2005) Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett. 579, 6027 6030.
36. Saido T. C. Iwata N. (2006) Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci. Res. 54, 235 253.
37. Sakai A., Ujike H., Nakata K. et al. (2004) Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 17, 164 169.
38. Sato M., Ikeda K., Haga S., Allsop D. Ishii T. (1991) A monoclonal antibody to common acute lymphoblastic leukemia antigen (neutral endopeptidase) immunostains senile plaques in the brains of patients with Alzheimer's disease. Neurosci. Lett. 121, 271 273.
39. Sayre L. M., Zelasko D. A., Harris P. L., Perry G., Salomon R. G. Smith M. A. (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68, 2092 2097.
40. Schuessel K., Schafer S., Bayer T. A., Czech C., Pradier L., Muller-Spahn F., Muller W. E. Eckert A. (2005) Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis. 18, 89 99.
41. Selkoe D. J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741 766.
42. Shi Q. Gibson G. E. (2007) Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 21, 276 291.
43. Shinall H., Song E. S. Hersh L. B. (2005) Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry. 44, 15345 15350.
44. Smith C. D., Carney J. M., Starke-Reed P. E., Oliver C. N., Stadtman E. R., Floyd R. A. Markesbery W. R. (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl Acad. Sci. USA 88, 10540 10543.
45. Smith M. A., Sayre L. M., Monnier V. M. Perry G. (1995) Radical ageing in Alzheimer's disease. Trends Neurosci. 18, 172 176.
46. Smith M. A., Rottkamp C. A., Nunomura A., Raina A. K. Perry G. (2000) Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502, 139 144.
47. Szweda L. I., Uchida K., Tsai L. Stadtman E. R. (1993) Inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Selective modification of an active-site lysine. J. Biol. Chem. 268, 3342 3347.
48. Takeda A., Smith M. A., Avila J., Nunomura A., Siedlak S. L., Zhu X., Perry G. Sayre L. M. (2000) In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J. Neurochem. 75, 1234 1241.
49. Turner A. J., Fisk L. Nalivaeva N. N. (2004) Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. Ann. NY Acad. Sci. 1035, 1 20.
50. Uchida K. Stadtman E. R. (1992) Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc. Natl Acad. Sci. USA 89, 4544 4548.
51. Uchida K. Stadtman E. R. (1993) Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J. Biol. Chem. 268, 6388 6393.
52. Varadarajan S., Yatin S., Aksenova M. Butterfield D. A. (2000) Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 184 208.
53. Vardy E. R., Catto A. J. Hooper N. M. (2005) Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med. 11, 464 472.
54. Wang D. S., Iwata N., Hama E., Saido T. C. Dickson D. W. (2003) Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 310, 236 241.
55. Wang D. S., Lipton R. B., Katz M. J., Davies P., Buschke H., Kuslansky G., Verghese J., Younkin S. G., Eckman C. Dickson D. W. (2005) Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J. Neuropathol. Exp. Neurol. 64, 378 385.
56. Wang D. S., Dickson D. W. Malter J. S. (2006) Beta-amyloid degradation and Alzheimer's disease. J. Biomed. Biotechnol. 2006, 58406.
57. Wang S., Simon B. P., Bennett D. A., Schneider J. A., Malter J. S. Wang D. S. (2007) The significance of pin1 in the development of Alzheimer's disease. J. Alzheimers Dis. 11, 13 23.
58. Wang D. S., Dickson D. W. Malter J. S. (2008) Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views. Int. J. Clin. Exp. Pathol. 1, 5 18.
59. Yankner B. A., Duffy L. K. Kirschner D. A. (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250, 279 282.
60. Yasojima K., McGeer E. G. McGeer P. L. (2001a) Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 919, 115 121.
61. Yasojima K., Akiyama H., McGeer E. G. McGeer P. L. (2001b) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 297, 97 100.